The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival (OS) of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns of 1,660 Japanese patients (pts).
 
Yoshida Kazushi
No Relationships to Disclose
 
Akira Inoue
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma
 
Shunichi Sugawara
Honoraria - AstraZeneca Japan; Chugai Pharma; Nippon Boehringer Ingelheim
 
Shuji Murakami
No Relationships to Disclose
 
Hideo Saka
Research Funding - AstraZeneca Japan (Inst); Bristol-Myers Squibb Japan (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Linical (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); West Japan Oncology Group (Inst)
 
Satoshi Morita
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly Japan
 
Young Hak Kim
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma
 
Fumio Imamura
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Merck Serono; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca Japan (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Koji Takeda
Honoraria - AstraZeneca Japan
Research Funding - AstraZeneca Japan (Inst)
 
Kazuhiko Nakagawa
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Pfizer
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Pfizer (Inst)
 
Masayuki Takeda
No Relationships to Disclose
 
Shinji Atagi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca Japan; Taiho Pharmaceutical
Research Funding - AstraZeneca Japan (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Yoshikazu Hasegawa
No Relationships to Disclose
 
Nobuyuki Yamamoto
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst)
 
Nobuyuki Katakami
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Janssen; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Hiroshige Yoshioka
Honoraria - Boehringer Ingelheim; Chugai Pharma; Lilly Japan
Research Funding - Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); Novartis (Inst)
 
Yasuo Iwamoto
No Relationships to Disclose
 
Isamu Okamoto
Honoraria - AstraZeneca Japan; Chugai Pharma; Lilly Japan; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca Japan
 
Takashi Seto
Honoraria - Chugai Pharma; Kyowa Hakko Kirin
Consulting or Advisory Role - Astellas Pharma; Daiichi Sankyo; Eisai; Ono Pharmaceutical; Sumitomo Dainippon
 
Yuichiro Ohe
Employment - Chugai Pharma (I)
Stock and Other Ownership Interests - Ono Pharmaceutical
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Lilly; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca Japan; Chugai Pharma; Lilly Japan; Novartis; Ono Pharmaceutical
Research Funding - Chugai Pharma (Inst)
Expert Testimony - AstraZeneca Japan